ReviewFrontiers in immunology2018
Exosomes and miRNA-Loaded Biomimetic Nanovehicles, a Focus on Their Potentials Preventing Type-2 Diabetes Linked to Metabolic Syndrome.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 59 citations in OpenAlex.
- MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program.International journal of molecular sciences · 2024Trial
- Milk-derived extracellular vesicles: nutritional significance, nano-delivery potential, and emerging therapeutic applications - an updated review.Food science of animal resources · 2026Review
- MicroRNA‑microbiome cross‑kingdom networks drive inflammatory bowel disease through dynamic regulatory ecosystems (Review).International journal of molecular medicine · 2026Review
- OMNIS: a spatially informed multi-omics deep-learning framework for tumor recurrence prediction and primary-metastatic tumor differentiation title page.Frontiers in artificial intelligence · 2026Article
- Exosomes in aging and age-related disorders: mechanisms, therapeutic potentials, and challenges.Journal of translational medicine · 2025Review
- Exosomes and microRNAs: Molecular Mediators Linking Obesity, Exercise, and Metabolic Regulation.Current diabetes reports · 2025Review
- From laboratory to clinic: a precise treatment strategy of mesenchymal stem cells-derived exosomes pretreated by simulating disease microenvironment.Frontiers in immunology · 2025Review
- MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome.Cancer cell international · 2024Review
- Human Breast Milk miRNAs: Their Diversity and Potential for Preventive Strategies in Nutritional Therapy.International journal of molecular sciences · 2023Review
- Genomic Editing and Diabetes.Advances in experimental medicine and biology · 2023Article
- Advancements in engineered exosomes for wound repair: current research and future perspectives.Frontiers in bioengineering and biotechnology · 2023Review
- miR-135a-5p overexpression in peripheral blood-derived exosomes mediates vascular injury in type 2 diabetes patients.Frontiers in endocrinology · 2023Article
- Oral Delivery of miR-320-3p with Lipidic Aminoglycoside Derivatives at Mid-Lactation Alters miR-320-3p Endogenous Levels in the Gut and Brain of Adult Rats According to Early or Regular Weaning.International journal of molecular sciences · 2022Article
- Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications.Journal of translational medicine · 2022Review
- Exosomes in cancer immunoediting and immunotherapy.Asian journal of pharmaceutical sciences · 2022Review
- Exosomes as Promising Nanostructures in Diabetes Mellitus: From Insulin Sensitivity to Ameliorating Diabetic Complications.International journal of nanomedicine · 2022Review
- Identification of miRNA signature for predicting the prognostic biomarker of squamous cell lung carcinoma.PloS one · 2022Article
- A brief glimpse of a tangled web in a small world: Tumor microenvironment.Frontiers in medicine · 2022Review
- Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review).Experimental and therapeutic medicine · 2021Review
- The double face of miR-320: cardiomyocytes-derived miR-320 deteriorated while fibroblasts-derived miR-320 protected against heart failure induced by transverse aortic constriction.Signal transduction and targeted therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are small membrane vesicles of 30-150 nm, members of the extracellular vesicle family and secreted by various cell types. Different studies describe specific microRNA (miRNA) with altered expression in serum and/or plasma of patients suffering from diabetes or metabolic syndrome. Diabetic cardiomyocyte-derived exosomes loaded with miRNAs like miR-320-3p (or 320a) have been shown regulating angiogenesis on endothelial cell cultures. Insufficient myocardial angiogenesis is the major manifestation of diabetes-caused ischemic cardiovascular disease. Studies on transfer of functional microRNAs between mouse dendritic cells via exosomes have shown that some miRNAs (miR-320-3p, 29b-3p, 7a-5p) are distributed in immature and mature exosomes. Among these miRNAs, miR-320-3p is better known in epigenetics for silencing polr3d gene by binding to its promoter in Human Embryonic Kidney-293 cells. Moreover, quantitative and stoichiometric analysis of the microRNA content of exosomes highlights the lack of reliable natural source of such particles loaded with miRNA opening the need for tailoring exosomes or nanoparticles delivering efficiently miRNA intimately linked to immunity, metabolism and epigenetics in target cells. However, loading of extracellular mature miRNA into recipient cells comes with a cost by at least impeding dynamic localization of miRNAs in nucleoli or inefficient miRNA delivery due to rapid recycling by exonucleases. All these works are calling for the design of new biomimetic vehicles and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.